Survival, Pathologic Response, and Genomics in CALGB 40601 (Alliance), a Neoadjuvant Phase III Trial of Paclitaxel-Trastuzumab With or Without Lapatinib in HER2-Positive Breast Cancer.

导出 OA

翻译打印收藏纠错

第一作者： Aranzazu,Fernandez-Martinez

第一单位： Lineberger Comprehensive Center, University of North Carolina, Chapel Hill, NC.;Department of Genetics, University of North Carolina, Chapel Hill, NC.

作者： Aranzazu,Fernandez-Martinez ^[1] ; Ian E,Krop ^[2] ; David W,Hillman ^[3] ; Mei-Yin,Polley ^[3] ; Joel S,Parker ^[1] ; Lucas,Huebner ^[3] ; Katherine A,Hoadley ^[1] ; Jonathan,Shepherd ^[1] ; Sara,Tolaney ^[2] ; N Lynn,Henry ^[4] ; Chau,Dang ^[5] ; Lyndsay,Harris ^[6] ; Donald,Berry ^[7] ; Olwen,Hahn ^[8] ; Clifford,Hudis ^[5] ; Eric,Winer ^[2] ; Ann,Partridge ^[2] ; Charles M,Perou ^[1] ; Lisa A,Carey ^[9]

作者单位： Lineberger Comprehensive Center, University of North Carolina, Chapel Hill, NC.;Department of Genetics, University of North Carolina, Chapel Hill, NC. ^[1] Department of Medical Oncology, Dana-Farber/Partners CancerCare, Boston, MA. ^[2] Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN. ^[3] University of Michigan Rogel Cancer Center, Ann Arbor, MI. ^[4] Memorial Sloan Kettering Cancer Center, New York, NY. ^[5] National Cancer Institute, Cancer Diagnostics Program, Bethesda, MD. ^[6] Division of Biostatistics, MD Anderson Cancer Center, Houston, TX. ^[7] Alliance Protocol Operations Office, University of Chicago, Chicago, IL. ^[8] Lineberger Comprehensive Center, University of North Carolina, Chapel Hill, NC.;Division of Hematology-Oncology, University of North Carolina, Chapel Hill, NC. ^[9]